Humasis Co

Humasis Co FCF Margin

The Free Cash Flow Margin of Humasis Co (205470.KQ) as of Nov 10, 2026 is 32.21 %. In the previous year, Free Cash Flow Margin was 114.06 % — a change of -71.76% (lower).

FCF Margin

32.21 %

YoY

-71.76%

Last updated:

Free Cash Flow Margin of Humasis Co is 2025 32.21 % . Free Cash Flow Margin of Humasis Co was 2024 114.06 % . It decreases by -71.76% lower compared to the previous year.

The Humasis Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-17.99 KRW
Jan 1, 2019
-24.12 KRW
Jan 1, 2020
-1.71 KRW
Jan 1, 2021
58.08 KRW
Jan 1, 2022
33.52 KRW
Jan 1, 2023
-569.86 KRW
Jan 1, 2024
114.06 KRW
Jan 1, 2025
32.21 KRW
The Humasis Co FCF Margin history
YEARFCF MarginYoY
32.21 %-71.76%
114.06 %-120.02%
-569.86 %-1,800.16%
33.52 %-42.29%
58.08 %-3,490.18%
-1.71 %-92.90%
-24.12 %+34.10%
-17.99 %-63.68%
-49.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Free Cash Flow Margin of Humasis Co is 32.21 % in 2025.

Free Cash Flow Margin of Humasis Co changed from 114.06 % to 32.21 %, representing a -71.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Humasis Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Humasis Co

All Key Metrics — Humasis Co